| Name | Title | Contact Details |
|---|
KCBIOMEDIX is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Redmond, WA, Medstreaming is a leading provider of Healthcare IT (“HCIT”) solutions for image intensive specialties. We are focused on enabling proactive patient care and increasing the efficiency of healthcare by providing medical IT solutions to individual practitioners and large institutions alike. Since its founding in 2006, Medstreaming has become a market leader in delivering specialty-based workflow applications that function as a “best of breed” specialties, including, but not limited to, Cardiology, Vascular, Vein & Surgery. Lead by a team of founding engineers, clinical specialists, and healthcare IT veterans, Medstreaming is committed to dramatically improving the delivery of healthcare and disease management, while becoming a global leader developing medical informatics solutions.
Invendo Medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology. Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendo medical´s goal is to improve patient compliance and thereby increase the number of procedures performed. In order to achieve its goal the company first focussed on an application in the diagnosis and treatment of colorectal cancers (CRC). CRC is the second leading cause of cancer death with an estimated annual worldwide death toll of 510,000 people. More than 1 million new cases are diagnosed every year. However 90-100% of colorectal cancers can be avoided if diagnosed early on
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.
In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.